BioNTech (NASDAQ:BNTX – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Bristol Myers and BioNTech are teaming up to develop and commercialize BNT327, a cancer therapy with blockbuster ambition.

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neuren Pharmaceuticals Limited (NURPF – Research Report), GlaxoSmithKline (GSK – Research Rep ...

Bristol-Myers Squibb has teamed up with BioNTech to co-develop a bispecific antibody, BNT327, targeting multiple solid tumors ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

German-based BioNTech (BNTX), best known for its collaboration with Pfizer (PFE) during the COVID-19 pandemic for developing ...

Truist Securities analysts raised the price target on BioNTech SE (NASDAQ:BNTX) from $151 to $155 and kept a “Buy” rating.

In the assessment of 12-month price targets, analysts unveil insights for BioNTech, presenting an average target of $138.7, a ...